VYNE VYNE Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VYNE

Price (delayed)

$2.62

Market cap

$36.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.78

Enterprise value

$6.48M

VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

Highlights
VYNE's equity has surged by 184% year-on-year
VYNE's EPS has soared by 72% QoQ and by 62% YoY
The net income has decreased by 23% YoY but it has increased by 12% from the previous quarter
The revenue is up by 20% since the previous quarter but it has declined by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://vynetherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VYNE
Market
Shares outstanding
14.1M
Market cap
$36.94M
Enterprise value
$6.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.41
Price to sales (P/S)
63.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.28
Earnings
Revenue
$424,000
EBIT
-$28.45M
EBITDA
-$28.45M
Free cash flow
-$25.34M
Per share
EPS
-$2.78
Free cash flow per share
-$2.47
Book value per share
$6.36
Revenue per share
$0.04
TBVPS
$9.51
Balance sheet
Total assets
$97.69M
Total liabilities
$8.95M
Debt
$214,000
Equity
$88.74M
Working capital
$88.43M
Liquidity
Debt to equity
0
Current ratio
12.73
Quick ratio
12.38
Net debt/EBITDA
1.07
Margins
EBITDA margin
-6,710.4%
Gross margin
100%
Net margin
-6,710.4%
Operating margin
-6,900.5%
Efficiency
Return on assets
-64.2%
Return on equity
-79.1%
Return on invested capital
-217.4%
Return on capital employed
-31.6%
Return on sales
-6,710.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VYNE stock price

How has the VYNE Therapeutics stock price performed over time
Intraday
4.8%
1 week
4.8%
1 month
-15.48%
1 year
-57.95%
YTD
12.45%
QTD
-14.66%

Financial performance

How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$424,000
Gross profit
$424,000
Operating income
-$29.26M
Net income
-$28.45M
Gross margin
100%
Net margin
-6,710.4%
VYNE's net margin is down by 38% year-on-year but it is up by 26% since the previous quarter
The net income has decreased by 23% YoY but it has increased by 12% from the previous quarter
VYNE's operating margin is up by 20% since the previous quarter and by 4% year-on-year
The revenue is up by 20% since the previous quarter but it has declined by 11% year-on-year

Growth

What is VYNE Therapeutics's growth rate over time

Valuation

What is VYNE Therapeutics stock price valuation
P/E
N/A
P/B
0.41
P/S
63.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.28
VYNE's EPS has soared by 72% QoQ and by 62% YoY
VYNE's equity has surged by 184% year-on-year
VYNE's P/B is 80% below its 5-year quarterly average of 2.0 and 41% below its last 4 quarters average of 0.7
VYNE's P/S is 67% above its last 4 quarters average of 38.0 and 30% above its 5-year quarterly average of 48.9
The revenue is up by 20% since the previous quarter but it has declined by 11% year-on-year

Efficiency

How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital has surged by 64% year-on-year
The ROE fell by 50% YoY but it rose by 47% QoQ
The ROA has contracted by 43% YoY but it has grown by 40% from the previous quarter
VYNE's ROS is down by 38% YoY but it is up by 26% QoQ

Dividends

What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYNE.

Financial health

How did VYNE Therapeutics financials performed over time
VYNE Therapeutics's total assets has soared by 140% YoY
VYNE's total liabilities is up by 15% since the previous quarter but it is down by 4.2% year-on-year
VYNE's debt is 100% smaller than its equity
VYNE's equity has surged by 184% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.